Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: GlaxoSmithKline | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: GlaxoSmithKline

Loss of Vesicare revenues hurts U.S. results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 1Q13*

1Q Revenues: £6.5 billion (-2%)

1Q: Earnings: £1.5 billion (-24%)

Comments: Combined pharmaceuticals and vaccines sales were down 2% (£5.1 billion), including a 6% drop in the U.S (£1.7 billion), -3% in Europe (£1.3 billion), and -6% in Japan (£447 million). Pharma sales worldwide were £4.4 billion (-1%) while vaccines fell 11% to £680 million. The respiratory franchise grew 6% to £1.9 billion, with Advair sales of £1.3 billion (+4%) and Flovent sales +7% to £213 million. The loss of Vesicare revenues, as a result of terminating a co-promotion partnership, led to a drop of £176 million in U.S. revenues. GSK announced plans to form a Global Established Products portfolio, covering more than 50 brands with 2012 sales of £3 billion, which will be be co-ordinated and reported separately from January 2014.

* All figures in GBP (£)

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters